Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
- Therapeutic Areas
Our expertise in the industry
Arrowhead Halts its ARO-ENaC Phase 1/2 Clinical Trial Arrowhead Pharmaceuticals recently notified about its voluntary decision to put a pause on its ongoing Phase 1/2 clinical study of AR...
Novavax targets approval for the COVID-19 vaccine in the USNovavax is targeting a second-quarter FDA filing for emergency use of its COVID-19 vaccine. The aim hints the U.S. could join the U.K...
Roche bets USD 120 Million on UCB's anti-tau Alzheimer's antibodyThe Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB's anti-tau antibody development. If every...
Olema Oncology raises USD 54 Million for breast cancer programOlema Oncology has raised USD 54 million to push its lead program into the clinic and boost its R&D efforts in other areas.&nb...
AbbVie, Sofinnova back USD 38 Million for Nitrome BiosciencesNitrome Biosciences contemplates treating Parkinson's disease and diabetes by targeting a new class of enzymes. The pharma raised U...
Immunomedics discontinues its trial early – hopes for accelerated approval of Sacituzumab govitecan for mTNBCImmunomedics- a New Jersey-based pharmaceutical company has announced to freeze its...
In advanced cancer patients, the most common site for the occurrence of metastasis is c...
Depression is a mental condition characterized by prolonged series of poor moods, loss ...
Myasthenia Gravis is an autoimmune disease that causes muscle weakness and fatigue. It ...
West syndrome is a rare form of neurological disorder, an age-related specific Epilepti...
Chronic diseases (CDs) pose a significant challenge to healthcare in the 21st century. ...
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
.png)
